Roche/Antisoma Ovarian Cancer Phase III Failure Likely To End Development
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Development for Roche/Antisoma’s ovarian cancer agent R-1549 is "unlikely" to continue following the biologic’s failure to meet primary endpoints in a pivotal Phase III trial, the companies said April 26.
You may also be interested in...
FDA Priority Review Voucher Redemption Fee Set At $4.6 Million In FY 2011
Redeeming a priority review voucher obtained by developing a drug for a tropical disease will cost companies $6.1 million in fiscal 2011